United Arab Emirates

Middle East

Contents

1. Regulatory Overview
2. Regulatory Pathways
3. Available Drugs

Regulatory Overview

United Arab Emirates is regulated by the MOHAP. The country has 1 documented regulatory pathway for accessing unapproved or unlicensed medicines, covering named patient programs, compassionate use schemes, and special access arrangements.

Regulatory Authority

MOHAP

Regulatory Pathways (1)

MOHAP Named Patient Program – UAE 14 days

UAE Ministry of Health and Prevention allows import of unregistered medicines for individual named patients under physician supervision and MOHAP approval.

Application Form: MOHAP NPP Application Form

Legal Basis: Federal Law No. 4 of 1983

Eligibility: Serious or life-threatening condition with no locally registered alternative

Reference: MOHAP Drug Policy

Drugs Available (1)

Drug	Access Route	Status	Lead Time
Nusinersen	Named Patient	Available via NPP	5 days

United Arab Emirates

ISO Code	`AE`
Region	Middle East
Regulatory Authority	MOHAP
Pathways	1 documented
Drugs Available	1 drug(s)